Axogen, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Basic and Diluted Loss per Common Share

Basic and Diluted Loss per Common Share

12 Months Ended

Dec. 31, 2022

The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method as of:


	December 31,
(in thousands, except per share amounts)		2022		2021		2020
Numerator:
Net loss		$	(28,948)	$	(26,985)	$	(23,786)
Denominator:
Weighted-average common shares outstanding (Basic)		42,083,125		41,214,889		39,966,937
Weighted-average common shares outstanding (Diluted)		42,083,125		41,214,889		39,966,937
Net loss per common share (Basic and Diluted)		$	(0.69)	$	(0.65)	$	(0.60)

Anti-dilutive shares excluded from the calculation of diluted earnings per share (1)
Stock options		3,133,865		1,364,567		1,618,002
Restricted stock units		454,430		333,276		188,321

(1) These common equivalent shares are not included in the diluted per share calculations as they would be anti-dilutive if the Company was in a net income position.